LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
28.03
+0.76 (2.79%)
May 20, 2026, 4:00 PM EDT - Market closed
LB Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, LB Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $45. The average 1-year stock price forecast is 60.54% higher than the current stock price, while the lowest is $34 (+21.30%) and the highest is $78 (+178.27%).
Price Target: $45 (+60.54%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LB Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +60.54% | Apr 27, 2026 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +28.43% | Apr 10, 2026 |
| Stifel | Stifel | Strong Buy Maintains $35 → $40 | Strong Buy | Maintains | $35 → $40 | +42.70% | Mar 27, 2026 |
| Stifel | Stifel | Strong Buy Maintains $27 → $35 | Strong Buy | Maintains | $27 → $35 | +24.87% | Dec 11, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $78 | Buy | Initiates | $78 | +178.27% | Oct 6, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.76
from -3.13
EPS Next Year
-4.48
from -3.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.68 | -3.94 | ||||||
| Avg | -3.76 | -4.48 | ||||||
| Low | -3.97 | -5.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.